Benutzer:FabianK/ICE

ICE bezeichnet eine Kombinationschemotherapie aus Ifosfamid, Carboplatin und Etoposid. Diese wird häufig angewendet um nicht-ansprechende (therapierefraktäre) oder rezidivierende maligne Lymphome zu behandeln.^[1]

In the last few years, it has become more common to include the drug rituximab alongside the ICE protocol, a regimen commonly referred to as R-ICE. Rituximab is a monoclonal antibody which binds to and helps destroy B cells.^[2]

↑ "Follow-up Care & Relapse." Lymphoma Research Foundation. http://www.lymphoma.org/site/pp.aspx?c=chKOI6PEImE&b=1574015&printmode=1
↑ "Trial of Oxaliplatin, Cytosine Arabinoside, Dexamethasone With Rituxan (ROAD) in Patients With Relapsed Non-Hodgkins Lymphoma." ClinicalTrials.gov. http://clinicaltrials.gov/show/NCT00166439

[1] "Follow-up Care & Relapse." Lymphoma Research Foundation. http://www.lymphoma.org/site/pp.aspx?c=chKOI6PEImE&b=1574015&printmode=1

[2] "Trial of Oxaliplatin, Cytosine Arabinoside, Dexamethasone With Rituxan (ROAD) in Patients With Relapsed Non-Hodgkins Lymphoma." ClinicalTrials.gov. http://clinicaltrials.gov/show/NCT00166439

[1]

[2]

Benutzer:FabianK/ICE

Navigationsmenü

Suche